Table 5.
Relationship between consumption of non-steroideal anti-inflammatory drugs and breast cancer, according to tumor characteristics
| Variable | Category | NSAID | Unexposed controls/cases (n) | Exposed controls/cases (n) | OR (95 % CI) | P |
|---|---|---|---|---|---|---|
| Clinical stage | 1–2 | NSAID (all) | 1170/696 | 739/404 | 0.80 (0.66–0.97 | 0.02 |
| Aspirin | 1807/1047 | 102/52 | 0.93 (0.63–1.38) | 0.72 | ||
| Acetic acid derivatives | 1753/1025 | 156/74 | 0.75 (0.54–1.06) | 0.11 | ||
| Propionic acid derivatives | 1350/770 | 559/329 | 0.90 (0.74–1.11) | 0.33 | ||
| cox2 inhibitors | 1891/1095 | 18/4 | - | - | ||
| NSAID others | 1861/1072 | 48/27 | 1.07 (0.61–1.90) | 0.81 | ||
| 3–4 | NSAID (all) | 1170/136 | 739/68 | 0.74 (0.51–1.06) | 0.10 | |
| Aspirin | 1807/192 | 102/12 | 1.31 (0.66–2.59) | 0.44 | ||
| Acetic acid derivatives | 1753/190 | 156/14 | 0.99 (0.53–1.83) | 0.97 | ||
| Propionic acid derivatives | 1350/147 | 559/57 | 0.84 (0.57–1.24) | 0.39 | ||
| cox2 inhibitors | 1891/204 | 18/0 | - | - | ||
| NSAID others | 1861/201 | 48/3 | - | - | ||
| Pathology | Ductal cancer | NSAID (all) | 1170/835 | 739/454 | 0.70 (0.58–0.84) | <0.001 |
| Aspirin | 1807/1225 | 102/64 | 0.97 (0.66–1.41) | 0.86 | ||
| Acetic acid derivatives | 1753/1204 | 156/85 | 0.76 (0.55–1.06) | 0.11 | ||
| Propionic acid derivatives | 1350/918 | 559/371 | 0.78 (0.64–0.95) | 0.01 | ||
| cox2 inhibitors | 1891/1289 | 18/3 | - | - | ||
| NSAID others | 1861/1259 | 48/30 | 1.06 (0.60–1.87) | 0.85 | ||
| Non-ductal cancer | NSAID (all) | 1170/151 | 739/83 | 0.82 (0.58–1.15) | 0.25 | |
| Aspirin | 1807/228 | 102/6 | 0.50 (0.21–1.19) | 0.12 | ||
| Acetic acid derivatives | 1753/219 | 156/15 | 0.85 (0.46–1.58) | 0.61 | ||
| Propionic acid derivatives | 1350/166 | 559/68 | 0.91 (0.63–1.31) | 0.60 | ||
| cox2 inhibitors | 1891/234 | 18/0 | - | - | ||
| NSAID others | 1861/232 | 48/2 | - | - | ||
| Inmunohistochemistry | Hormone + | NSAID (all) | 1170/727 | 739/390 | 0.72 (0.60–0.88) | <0.001 |
| Aspirin | 1807/1069 | 102/48 | 0.82 (0.55–1.24) | 0.35 | ||
| Acetic acid derivatives | 1753/1044 | 156/73 | 0.76 (0.54–1.08) | 0.12 | ||
| Propionic acid derivatives | 1350/805 | 559/312 | 0.80 (0.65–0.98) | 0.03 | ||
| cox2 inhibitors | 1891/1115 | 18/2 | - | - | ||
| NSAID others | 1861/1089 | 48/28 | 1.28 (0.73–2.25) | 0.38 | ||
| HER2+ | NSAID (all) | 1170/739 | 172/83 | 0.63 (0.45–0.88) | 0.007 | |
| Aspirin | 1807/102 | 244/11 | 0.79 (0.38–1.65) | 0.53 | ||
| Acetic acid derivatives | 1753/238 | 156/17 | 0.67 (0.36–1.24) | 0.20 | ||
| Propionic acid derivatives | 1350/188 | 559/67 | 0.66 (0.46–0.95) | 0.03 | ||
| cox2 inhibitors | 1891/255 | 18/0 | - | - | ||
| NSAID others | 1861/251 | 48/4 | - | - | ||
| Triple negative breast cancer | NSAID (all) | 1170/94 | 739/63 | 0.87 (0.58–1.30) | 0.49 | |
| Aspirin | 1807/148 | 102/9 | 1.24 (0.57–2.71) | 0.59 | ||
| Acetic acid derivatives | 1753/147 | 156/10 | 0.86 (0.41–1.79) | 0.68 | ||
| Propionic acid derivatives | 1350/103 | 559/54 | 0.99 (0.64–1.52) | 0.95 | ||
| cox2 inhibitors | 1891/156 | 18/1 | - | - | ||
| NSAID others | 1861/154 | 48/3 | - | - |
OR Odds ratio adjusted for age, recruitment area, education level, tobacco smoking history, BMI family history of breast cancer, number of deliveries, age at first delivery, menarche age, and menopausal status. CI confidence interval